Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Generali Asset Management SPA SGR has purchased 11,358 shares of Regeneron Pharmaceuticals, valued at approximately $8.1 ...

Asian Paints Q4 Results: Weak demand drags company’s sales, profit below view Weak demand ahead of the general elections, along with price cuts taken by the company amid intense competition weighed on ...